Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The H10 EORTC/GELA/IIL Randomized Intergroup Trial on Early FDG-PET Scan Guided Treatment Adaptation Versus Standard Combined Modality Treatment in Patients With Supradiaphragmatic Stage I/II Hodgkin's Lymphoma
Brief Summary: RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. Diagnostic procedures, such as fludeoxyglucose F 18 positron emission tomography (FDG-PET scan), may help doctors predict a patient's response to treatment and help plan the best treatment. It is not yet known whether FDG-PET scan-guided therapy is more effective than standard therapy in treating Hodgkin's lymphoma.

PURPOSE: This randomized phase III trial is studying FDG-PET scan-guided therapy to see how well it works compared with standard therapy in treating patients with previously untreated stage I or stage II Hodgkin's lymphoma.


Options:
A: Arm Label: Arm I (Patients off-therapy before callback-Induction only); Type: EXPERIMENTAL; Interventions: Biological: Bleomycin Sulfate, Drug: Cyclophosphamide, Drug: Doxorubicin Hydrochloride, Drug: Etoposide, Biological: Filgrastim, Drug: Prednisone, Drug: Vincristine Sulfate Liposome | Arm Label: Arm II (RER with CR [ABVE-PC, IFRT]); Type: EXPERIMENTAL; Interventions: Biological: Bleomycin Sulfate, Drug: Cyclophosphamide, Drug: Doxorubicin Hydrochloride, Drug: Etoposide, Biological: Filgrastim, Radiation: Involved-Field Radiation Therapy, Drug: Prednisone, Drug: Vincristine Sulfate Liposome | Arm Label: Arm III (RER with CR [ABVE-PC]); Type: EXPERIMENTAL; Interventions: Biological: Bleomycin Sulfate, Drug: Cyclophosphamide, Drug: Doxorubicin Hydrochloride, Drug: Etoposide, Biological: Filgrastim, Drug: Prednisone, Drug: Vincristine Sulfate Liposome | Arm Label: Arm IV (RER with less than CR [ABVE-PC, IFRT]); Type: EXPERIMENTAL; Interventions: Biological: Bleomycin Sulfate, Drug: Cyclophosphamide, Drug: Doxorubicin Hydrochloride, Drug: Etoposide, Biological: Filgrastim, Radiation: Involved-Field Radiation Therapy, Drug: Prednisone, Drug: Vincristine Sulfate Liposome | Arm Label: Arm V (RER with PD); Type: EXPERIMENTAL; Interventions: Biological: Bleomycin Sulfate, Drug: Cyclophosphamide, Drug: Doxorubicin Hydrochloride, Drug: Etoposide, Biological: Filgrastim, Drug: Prednisone, Drug: Vincristine Sulfate Liposome | Arm Label: Arm VI (SER [DECA, ABVE-PC, IFRT]); Type: EXPERIMENTAL; Interventions: Biological: Bleomycin Sulfate, Drug: Cisplatin, Drug: Cyclophosphamide, Drug: Cytarabine, Drug: Dexamethasone, Drug: Doxorubicin Hydrochloride, Drug: Etoposide, Biological: Filgrastim, Radiation: Involved-Field Radiation Therapy, Drug: Prednisone, Drug: Vincristine Sulfate Liposome | Arm Label: Arm VII (SER [ABVE-PC, IFRT]); Type: EXPERIMENTAL; Interventions: Biological: Bleomycin Sulfate, Drug: Cyclophosphamide, Drug: Doxorubicin Hydrochloride, Drug: Etoposide, Biological: Filgrastim, Radiation: Involved-Field Radiation Therapy, Drug: Prednisone, Drug: Vincristine Sulfate Liposome | Intervention Type: BIOLOGICAL; Name: Bleomycin Sulfate; Assigned to Arm(s): Arm I (Patients off-therapy before callback-Induction only), Arm II (RER with CR [ABVE-PC, IFRT]), Arm III (RER with CR [ABVE-PC]), Arm IV (RER with less than CR [ABVE-PC, IFRT]), Arm V (RER with PD), Arm VI (SER [DECA, ABVE-PC, IFRT]), Arm VII (SER [ABVE-PC, IFRT]) | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Arm VI (SER [DECA, ABVE-PC, IFRT]) | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Arm I (Patients off-therapy before callback-Induction only), Arm II (RER with CR [ABVE-PC, IFRT]), Arm III (RER with CR [ABVE-PC]), Arm IV (RER with less than CR [ABVE-PC, IFRT]), Arm V (RER with PD), Arm VI (SER [DECA, ABVE-PC, IFRT]), Arm VII (SER [ABVE-PC, IFRT]) | Intervention Type: DRUG; Name: Cytarabine; Assigned to Arm(s): Arm VI (SER [DECA, ABVE-PC, IFRT]) | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Arm VI (SER [DECA, ABVE-PC, IFRT]) | Intervention Type: DRUG; Name: Doxorubicin Hydrochloride; Assigned to Arm(s): Arm I (Patients off-therapy before callback-Induction only), Arm II (RER with CR [ABVE-PC, IFRT]), Arm III (RER with CR [ABVE-PC]), Arm IV (RER with less than CR [ABVE-PC, IFRT]), Arm V (RER with PD), Arm VI (SER [DECA, ABVE-PC, IFRT]), Arm VII (SER [ABVE-PC, IFRT]) | Intervention Type: DRUG; Name: Etoposide; Assigned to Arm(s): Arm I (Patients off-therapy before callback-Induction only), Arm II (RER with CR [ABVE-PC, IFRT]), Arm III (RER with CR [ABVE-PC]), Arm IV (RER with less than CR [ABVE-PC, IFRT]), Arm V (RER with PD), Arm VI (SER [DECA, ABVE-PC, IFRT]), Arm VII (SER [ABVE-PC, IFRT]) | Intervention Type: BIOLOGICAL; Name: Filgrastim; Assigned to Arm(s): Arm I (Patients off-therapy before callback-Induction only), Arm II (RER with CR [ABVE-PC, IFRT]), Arm III (RER with CR [ABVE-PC]), Arm IV (RER with less than CR [ABVE-PC, IFRT]), Arm V (RER with PD), Arm VI (SER [DECA, ABVE-PC, IFRT]), Arm VII (SER [ABVE-PC, IFRT]) | Intervention Type: RADIATION; Name: Involved-Field Radiation Therapy; Assigned to Arm(s): Arm II (RER with CR [ABVE-PC, IFRT]), Arm IV (RER with less than CR [ABVE-PC, IFRT]), Arm VI (SER [DECA, ABVE-PC, IFRT]), Arm VII (SER [ABVE-PC, IFRT]) | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Arm I (Patients off-therapy before callback-Induction only), Arm II (RER with CR [ABVE-PC, IFRT]), Arm III (RER with CR [ABVE-PC]), Arm IV (RER with less than CR [ABVE-PC, IFRT]), Arm V (RER with PD), Arm VI (SER [DECA, ABVE-PC, IFRT]), Arm VII (SER [ABVE-PC, IFRT]) | Intervention Type: DRUG; Name: Vincristine Sulfate Liposome; Assigned to Arm(s): Arm I (Patients off-therapy before callback-Induction only), Arm II (RER with CR [ABVE-PC, IFRT]), Arm III (RER with CR [ABVE-PC]), Arm IV (RER with less than CR [ABVE-PC, IFRT]), Arm V (RER with PD), Arm VI (SER [DECA, ABVE-PC, IFRT]), Arm VII (SER [ABVE-PC, IFRT])
B: Arm Label: Radiotherapy or ABVD + Radiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Biological: bleomycin sulfate, Drug: dacarbazine, Drug: doxorubicin hydrochloride, Drug: vinblastine, Radiation: radiation therapy | Arm Label: ABVD Alone; Type: ACTIVE_COMPARATOR; Interventions: Biological: bleomycin sulfate, Drug: dacarbazine, Drug: doxorubicin hydrochloride, Drug: vinblastine | Intervention Type: BIOLOGICAL; Name: bleomycin sulfate; Assigned to Arm(s): ABVD Alone, Radiotherapy or ABVD + Radiotherapy | Intervention Type: DRUG; Name: dacarbazine; Assigned to Arm(s): ABVD Alone, Radiotherapy or ABVD + Radiotherapy | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): ABVD Alone, Radiotherapy or ABVD + Radiotherapy | Intervention Type: DRUG; Name: vinblastine; Assigned to Arm(s): ABVD Alone, Radiotherapy or ABVD + Radiotherapy | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): Radiotherapy or ABVD + Radiotherapy
C: Arm Label: Arm A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Adriamycin, Drug: Bleomycin, Drug: Vinblastine, Drug: DTIC, Radiation: 30 Gy IF-RT | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: Adriamycin, Drug: Bleomycin, Drug: Vinblastine, Drug: DTIC, Radiation: 20 Gy IF-RT | Arm Label: Arm C; Type: EXPERIMENTAL; Interventions: Drug: Adriamycin, Drug: Bleomycin, Drug: Vinblastine, Drug: DTIC, Radiation: 30 Gy IF-RT | Arm Label: Arm D; Type: EXPERIMENTAL; Interventions: Drug: Adriamycin, Drug: Bleomycin, Drug: Vinblastine, Drug: DTIC, Radiation: 20 Gy IF-RT | Intervention Type: DRUG; Name: Adriamycin; Assigned to Arm(s): Arm A, Arm B, Arm C, Arm D | Intervention Type: DRUG; Name: Bleomycin; Assigned to Arm(s): Arm A, Arm B, Arm C, Arm D | Intervention Type: DRUG; Name: Vinblastine; Assigned to Arm(s): Arm A, Arm B, Arm C, Arm D | Intervention Type: DRUG; Name: DTIC; Assigned to Arm(s): Arm A, Arm B, Arm C, Arm D | Intervention Type: RADIATION; Name: 30 Gy IF-RT; Assigned to Arm(s): Arm A, Arm C | Intervention Type: RADIATION; Name: 20 Gy IF-RT; Assigned to Arm(s): Arm B, Arm D
D: Arm Label: Favorable - Standard - any PET outcome; Type: ACTIVE_COMPARATOR; Interventions: Drug: ABVD q4 weeks, Radiation: IN-RT 30 Gy (+ boost 6 Gy residual), Procedure: FDG-PET scan | Arm Label: Favorable - Experimental - PET negative; Type: EXPERIMENTAL; Interventions: Drug: ABVD q4 weeks, Procedure: FDG-PET scan | Arm Label: Favorable - Experimental - PET positive; Type: EXPERIMENTAL; Interventions: Drug: BEACOPP escalated q3 weeks, Radiation: IN-RT 30 Gy (+ boost 6 Gy residual), Procedure: FDG-PET scan | Arm Label: Unfavorable - Standard - Any PET outcome; Type: ACTIVE_COMPARATOR; Interventions: Drug: ABVD q4 weeks, Radiation: IN-RT 30 Gy (+ boost 6 Gy residual), Procedure: FDG-PET scan | Arm Label: Unfavorable - Experimental - PET negative; Type: EXPERIMENTAL; Interventions: Drug: ABVD q4 weeks, Procedure: FDG-PET scan | Arm Label: Unfavorable - Experimental - PET positive; Type: EXPERIMENTAL; Interventions: Drug: BEACOPP escalated q3 weeks, Radiation: IN-RT 30 Gy (+ boost 6 Gy residual), Procedure: FDG-PET scan | Intervention Type: DRUG; Name: ABVD q4 weeks; Assigned to Arm(s): Favorable - Experimental - PET negative, Favorable - Standard - any PET outcome, Unfavorable - Experimental - PET negative, Unfavorable - Standard - Any PET outcome | Intervention Type: DRUG; Name: BEACOPP escalated q3 weeks; Assigned to Arm(s): Favorable - Experimental - PET positive, Unfavorable - Experimental - PET positive | Intervention Type: RADIATION; Name: IN-RT 30 Gy (+ boost 6 Gy residual); Assigned to Arm(s): Favorable - Experimental - PET positive, Favorable - Standard - any PET outcome, Unfavorable - Experimental - PET positive, Unfavorable - Standard - Any PET outcome | Intervention Type: PROCEDURE; Name: FDG-PET scan; Assigned to Arm(s): Favorable - Experimental - PET negative, Favorable - Experimental - PET positive, Favorable - Standard - any PET outcome, Unfavorable - Experimental - PET negative, Unfavorable - Experimental - PET positive, Unfavorable - Standard - Any PET outcome

Answer: D